@article{5320567ccfcd419786411b156bf34e64,
title = "C3 glomerulopathy: Consensus report",
abstract = "C3 glomerulopathy is a recently introduced pathological entity whose original definition was glomerular pathology characterized by C3 accumulation with absent or scanty immunoglobulin deposition. In August 2012, an invited group of experts (comprising the authors of this document) in renal pathology, nephrology, complement biology, and complement therapeutics met to discuss C3 glomerulopathy in the first C3 Glomerulopathy Meeting. The objectives were to reach a consensus on: the definition of C3 glomerulopathy, appropriate complement investigations that should be performed in these patients, and how complement therapeutics should be explored in the condition. This meeting report represents the current consensus view of the group.",
keywords = "clinical immunology, clinical nephrology, complement, glomerulonephritis, immunology and pathology",
author = "Pickering, {Matthew C.} and D'agati, {Vivette D.} and Nester, {Carla M.} and Smith, {Richard J.} and Mark Haas and Appel, {Gerald B.} and Alpers, {Charles E.} and Bajema, {Ingeborg M.} and Camille Bedrosian and Michael Braun and Mittie Doyle and Fadi Fakhouri and Fervenza, {Fernando C.} and Fogo, {Agnes B.} and V{\'e}ronique Fr{\'e}meaux-Bacchi and Gale, {Daniel P.} and {Goicoechea De Jorge}, Elena and Gene Griffin and Harris, {Claire L.} and Holers, {V. Michael} and Sally Johnson and Lavin, {Peter J.} and Nicholas Medjeral-Thomas and {Paul Morgan}, B. and Nast, {Cynthia C.} and Noel, {Laure H{\'e}l{\`e}ne} and Peters, {D. Keith} and {Rodr{\'i}guez De C{\'o}rdoba}, Santiago and Aude Servais and Sanjeev Sethi and Song, {Wen Chao} and Paul Tamburini and Thurman, {Joshua M.} and Michael Zavros and Cook, {H. Terence}",
note = "Funding Information: GBA is a consultant to Alexion Pharmaceuticals and Genentech and a Principal Investigator for an Alexion-funded research grant. FF has received fees from Alexion Pharmaceuticals for invited lectures and is member of an expert board supported by Alexion Pharmaceuticals. VF-B has received fees from Alexion Pharmaceuticals for invited lectures and is member of an expert board supported by Alexion Pharmaceuticals. VMH is a consultant to Alexion Pharmaceuticals, has received sponsored research from Taligen Therapeutics and Alexion, and has received licensing and royalty fees from Taligen and Alexion. SJ is a member of a scientific advisory board for Alexion Phamaceuticals. BPM is a consultant for Baxter International. CMN is a participant on the C3 Glomerulopathy Advisory Board, sponsored by Alexion Pharmaceuticals. DKP is a consultant for GlaxoSmithKline. MCP has received fees from Alexion Pharmaceuticals for invited lectures and funding for pre-clinical studies on experimental complement reagents. JMT is a paid consultant for Alexion Pharmaceuticals. CB, MD, GG, and PT are employees of Alexion Pharmaceuticals and own stock or stock options. SRdC has received fees from Alexion Pharmaceuticals for invited lectures and consultancy. CLH has an employment contract with GlaxoSmithKline. The remaining authors declared no competing interests. ",
year = "2013",
month = dec,
doi = "10.1038/ki.2013.377",
language = "English (US)",
volume = "84",
pages = "1079--1089",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",
}